Close
The FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot has become increasingly relevant for medical device innovators developing technologies intended to address significant unmet clinical needs. On July 1, 2026, FDA expanded TAP enrollment across all Offices of Health Technologies within CDRH for eligible devices with Breakthrough Device designation or participation in the Safer Technologies Program (STeP). As of that date, FDA reported 133 devices enrolled in the pilot.
For sponsors, this expansion reinforces an important principle: regulatory engagement, clinical development strategy, evidence planning, and patient-access considerations increasingly need to be aligned earlier in the device lifecycle.
TAP stands for the Total Product Life Cycle Advisory Program.
FDA describes TAP as a voluntary program intended to accelerate development of high-quality, safe, effective, and innovative medical devices that are important to public health. The program is designed around early, frequent, and strategic communication with FDA, supported by dedicated TAP advisors. The program goes beyond simply discussing an eventual marketing submission. Its broader purpose is to help sponsors identify development challenges earlier and better understand the path from product development to market and patient access.
That makes TAP particularly relevant to companies still shaping their:
FDA’s July 2026 expansion opened TAP enrollment requests across all CDRH Offices of Health Technologies for eligible Breakthrough-designated and STeP devices. FDA’s current enrollment framework also anticipates continued expansion through FY2027.
This is significant because more device developers may now have an opportunity to engage with FDA through a structured total-product-lifecycle model rather than waiting until major development decisions have already been made. The strongest value of that engagement may come before pivotal evidence generation, when sponsors still have the ability to adjust development strategy.
Under FDA’s current criteria, candidate devices generally need to have either:
FDA also emphasizes early-stage development. For example, the device should generally not yet have initiated its pivotal study, and the program includes restrictions regarding prior device-related Pre-Submissions after Breakthrough designation or STeP acceptance.
FDA currently does not intend to enroll combination products in the pilot, and CBER-regulated devices are not eligible under the present criteria. Eligibility alone, however, should not be viewed as the clinical development strategy. Sponsors still need a clear evidence plan before and during FDA engagement.
TAP reflects a broader shift toward total product lifecycle thinking.
Instead of treating regulatory interaction, clinical development, quality planning, risk management, and commercialization as separate activities, sponsors increasingly need to understand how decisions in one area affect the others.
For an innovative device, a decision about intended use may influence:
Intended Use → Target Population → Clinical Endpoints → Study Design → Evidence Requirements → Submission Strategy → Adoption
That chain should ideally be considered before a pivotal study is designed.
Intended use, indications for use, device configuration, development status, and target population.
Existing evidence, evidence gaps, study sequence, endpoints, and planned clinical investigations.
Known hazards, risk controls, residual risks, and how clinical evidence relates to the risk-management process.
Expected marketing pathway, relevant FDA interactions, clinical evidence needs, and submission milestones.
Development activities should be integrated within the manufacturer’s quality management system, including applicable ISO 13485 and FDA Quality Management System Regulation requirements.
Anticipated performance monitoring, real-world evidence needs, and lifecycle development requirements.
Dynamill Research helps medical device, diagnostic, IVD, digital health, and emerging-technology sponsors build clinical development programs before individual studies are locked in.
Our Clinical Development Services support areas such as:
For sponsors pursuing Breakthrough designation, STeP, TAP, or other FDA pathways, early development planning can help make regulatory interactions more focused and actionable.